MedPath

Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke

Prevention of Diabetes and Hypertension

Phase 4
Terminated
Conditions
Diabetes Mellitus
Hypertension
Interventions
Behavioral: Diet
Behavioral: Moderate exercise
Drug: placebo tablets
First Posted Date
2007-04-05
Last Posted Date
2024-02-20
Lead Sponsor
Istituto Auxologico Italiano
Target Recruit Count
3000
Registration Number
NCT00456963
Locations
🇮🇹

Istituto Auxologico Italiano., Milan, Italy

A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)

Phase 3
Terminated
Conditions
Hypertension
Interventions
First Posted Date
2007-03-15
Last Posted Date
2024-06-18
Lead Sponsor
Organon and Co
Target Recruit Count
40
Registration Number
NCT00447603

Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy

Phase 3
Completed
Conditions
Hypertension; Hypertrophy, Left Ventricular
Interventions
First Posted Date
2007-03-13
Last Posted Date
2011-05-11
Lead Sponsor
Novartis
Target Recruit Count
90
Registration Number
NCT00446563
Locations
🇩🇪

25 centers in Germany, Ludwigshafen, Germany

Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome

Phase 3
Completed
Conditions
Marfan Syndrome
Interventions
First Posted Date
2007-01-31
Last Posted Date
2025-03-07
Lead Sponsor
Carelon Research
Target Recruit Count
608
Registration Number
NCT00429364
Locations
🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Lucile Packard Children's Hospital, Palo Alto, California, United States

🇺🇸

Rady Children's Hospital / UCSD, San Diego, California, United States

and more 23 locations

Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus

Phase 4
Completed
Conditions
Macroalbuminuric Diabetic Nephropathy
First Posted Date
2007-01-09
Last Posted Date
2011-08-04
Lead Sponsor
University of Sao Paulo
Target Recruit Count
80
Registration Number
NCT00419835
Locations
🇧🇷

Nephrology Department, Sao Paulo University Medical School, Sao Paulo, Brazil

Telmisartan and Losartan in Hypertensive IGT

Phase 4
Completed
Conditions
Hypertension
Impaired Glucose Tolerance
First Posted Date
2006-12-05
Last Posted Date
2006-12-05
Lead Sponsor
Medical University of Graz
Target Recruit Count
24
Registration Number
NCT00407862
Locations
🇦🇹

Medical University of Graz, Graz, Austria

Treating the Endothelium to Restore Insulin Sensitivity

Not Applicable
Completed
Conditions
Impaired Glucose Tolerance
Obesity
Pre-diabetes
Insulin Resistance
First Posted Date
2006-11-22
Last Posted Date
2013-09-24
Lead Sponsor
Indiana University School of Medicine
Target Recruit Count
17
Registration Number
NCT00402194
Locations
🇺🇸

Indiana University Hospital GCRC, Indianapolis, Indiana, United States

Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients (0954A-322)

Phase 3
Completed
Conditions
Hypertension
First Posted Date
2006-11-10
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
41
Registration Number
NCT00398541

Improving Outcomes in Patients With Kidney Disease Due to Diabetes

Phase 2
Completed
Conditions
Diabetes
Kidney Disease
Hypertension
First Posted Date
2006-09-27
Last Posted Date
2010-03-02
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
92
Registration Number
NCT00381134
Locations
🇺🇸

The University of Texas Southwestern Medical Center, Dallas, Texas, United States

Specific Blockage of Angiotensine 2 and Podocyturia in Glomerular Nephropathies With Hypertension and Proteinuria

Phase 4
Suspended
Conditions
Proteinuria
End Stage Renal Disease
Hypertension
Interventions
First Posted Date
2006-08-29
Last Posted Date
2009-02-18
Lead Sponsor
University Hospital, Strasbourg, France
Target Recruit Count
20
Registration Number
NCT00369538
Locations
🇫🇷

Service de Néphrologie, Hôpital Civil, Hôpitaux Universitaires, Strasbourg, France

© Copyright 2025. All Rights Reserved by MedPath